Episode

Episode 505 : ASCO 2026 - RAMPART

Podcast: The Uromigos
Published: May 30, 2026
Duration seconds: 1771
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-505--ASCO-2026---RAMPART-e3jl61f
Audio: https://anchor.fm/s/13347ea8/podcast/play/120280559/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424542149-44100-2-d2b1721d3afce.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-505-asco-2026-rampart
Markdown: /podcast/the-uromigos-1214845/episode-505-asco-2026-rampart.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-505-asco-2026-rampart/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-505-asco-2026-rampart.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.